adverse events

Complications Associated with Offloading: Results of a Randomized Controlled Trial

Objective: To compare the frequency of adverse events between groups treated with total contact cast (TCC), instant total contact cast (iTCC), and removable cast walker (RCW). Methodology...

Douglas P. Murdoch , DPM;

Lawrence A. Lavery , DPM, MPH;

Amanda L. Killeen , DPM;

David G. Armstrong , DPM, MD, PhD, MSc;

08/19/2021

News

Isatuximab Combination Effective in Myeloma and Soft-Tissue Plasmacytomas

06/22/2020

Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...

...

06/22/2020

Journal of Clinical Pathways

News

Venetoclax-Based Time-Limited Therapy Well Tolerated, Effective in CLL

06/10/2020

Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...

...

06/10/2020

Journal of Clinical Pathways

News

Real-World Costs of Adverse Events After First-Line Treatment of Metastatic NSCLC

06/09/2020

Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...

...

06/09/2020

Journal of Clinical Pathways

News

Effective, Less Toxic Treatment Option Identified for Aggressive B-Cell Lymphoma

05/29/2020

Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...

...

05/29/2020

Journal of Clinical Pathways

News

Hypercalcemia as a Biomarker for Aggressive Disease in Patients With B-Cell Lymphoma

05/13/2020

For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...

For...

05/13/2020

Journal of Clinical Pathways

News

High Risk of Preventable and Mitigable Adverse Events in Cancer Care

08/22/2017

JCP Editors

Researchers have identified a significant burden of adverse events across the cancer care continuum, including preventable or mitigable events, according to a study published in Cancer (online August 17, 2017;...

...

08/22/2017

Journal of Clinical Pathways

Research in Review

11/30/2016

JCP Editors

Two kinds of heart medications, angiotensin-converting enzyme (ACE) inhibitors and beta blockers, can help to prevent a decline in heart function from breast cancer treatment, according to new research published in...

Two...

11/30/2016

Journal of Clinical Pathways

Algorithm Improves Adverse Event Response for Patients Receiving Immunotherapies

05/02/2016

JCP Editors

A standard algorithm created by a nurse-led collaborative team helped clinicians better assess and manage adverse events in patients receiving immunotherapy for cancer, according to an oral presentation at the...

A...

05/02/2016

Journal of Clinical Pathways

Original Contribution

Effect of Prior Aspirin Treatment on Patients With Acute Coronary Syndromes: Insights From the PROSPECT Study

07/15/2015

Bernard De Bruyne , MD, PhD;

Giora Weisz , MD;

Akiko Maehara , MD;

Gregg W. Stone , MD, FACC, FSCAI;

Sorin J. Brener , MD;

Patrick W. Serruys , MD, PhD;

Gary S. Mintz , MD;

Prior aspirin treatment is considered a risk factor for adverse outcomes in ACS patients. This PROSPECT trial analysis of patients with versus without aspirin pretreatment indicates that aspirin pretreatment was not an independent predictor...

Prior aspirin treatment is...

07/15/2015

Journal of Invasive Cardiology